Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Image source: Getty Images. Novo's trial disappoints Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug.

Novo Nordisk NOVO.B 2.82% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster treatment, an early-stage trial showed, as the drugmaker races to develop ...

Novo Nordisk ends its partnership with Hims & Hers over safety concerns with Wegovy distribution, citing regulatory issues and counterfeit drug risks. Read more here.

Novo Nordisk NVO ended its collaboration agreement with telehealth company Hims & Hers Health HIMS to offer its blockbuster obesity drug Wegovy (semaglutide) at a discounted price to cash-paying ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

June 22 (Reuters) - Novo Nordisk (NOVOb.CO) on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to ...